A phase 1, open-label, dose escalation and dose expansion, multicenter clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lomonitinib (ZE46-0134) in adults with FLT3-mutated relapsed or refractory acute myeloid leukemia Meeting Abstract
| Authors: | Lin, T. L.; Koenig, K. L.; Swords, R. T.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; Blum, W.; Schiller, G. J.; Zeidner, J. F.; Curran, E. K.; Martycz, M.; Rosenberg, L.; Marcus, S. G.; Chen, T.; Stefanos, M.; Burd, A.; Yocum, A. O.; Levine, R. L.; Druker, B. J.; Borate, U.; Byrd, J. C.; Mims, A. |
| Abstract Title: | A phase 1, open-label, dose escalation and dose expansion, multicenter clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lomonitinib (ZE46-0134) in adults with FLT3-mutated relapsed or refractory acute myeloid leukemia |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 2883.4 |
| Language: | English |
| ACCESSION: | WOS:001415696500049 |
| DOI: | 10.1182/blood-2024-208822 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work